In a report released today, Derek Archila from Stifel Nicolaus reiterated a Buy rating on Prometheus Biosciences (RXDX), with a price target of $25.00. The company’s shares closed last Friday at $17.50, close to its 52-week low of $16.11.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.9% and a 41.9% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Prometheus Biosciences is a Strong Buy with an average price target of $32.25.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RXDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of…
